U-93631 is a GABAA receptor antagonist.
Names | |
---|---|
IUPAC name
tert-butyl 4,4-dimethyl-5H-imidazo[1,5-a]quinoxaline-3-carboxylate
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C17H21N3O2 | |
Molar mass | 299.374 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Mechanism of action
editThe mechanism of action of this compound is not entirely clear, but research shows that it binds to the GABAA receptor. Its binding site seems to be similar to the one of picrotoxin, a potent neurotoxin and convulsant.
The binding of U-93631 decreases the probability of the chloride channel opening and stabilizes the receptor in an inactivated state.[1]
References
edit- ^ Dillon, G. H.; Im, W. B.; Pregenzer, J. F.; Carter, D. B.; Hamilton, B. J. (February 1995). "[4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability". The Journal of Pharmacology and Experimental Therapeutics. 272 (2): 597–603. ISSN 0022-3565. PMID 7531762.